{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:33:36Z","timestamp":1794929616089,"version":"4.9.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Surgery and postoperative adjuvant therapy is the standard treatment for locally advanced resectable oral squamous cell carcinoma (OSCC), while neoadjuvant chemoimmunotherapy (NACI) is believed to lead to better outcomes. This study aims to investigate the effectiveness of NACI regimens in treating locally advanced resectable OSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>Patients diagnosed with locally advanced resectable OSCC who received NACI and non-NACI were reviewed between December 2020 and June 2022 in our single center. The pathologic response was evaluated to the efficacy of NACI treatment. Adverse events apparently related to NACI treatment were graded by Common Terminology Criteria for Adverse Events, version 5.0. The disease-free survival (DFS) and overall survival (OS) rate were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our analysis involved 104 patients who received NACI. Notably, the pathological complete response rate was 47.1%, and the major pathological response (MPR) rate was 65.4%. The top three grade 1\u20132 treatment-related adverse events (TRAEs) were alopecia (104; 100%), anemia (81; 77.9%), and pruritus (62; 59.6%). Importantly, patients achieving MPR exhibited higher programmed cell death-ligand 1 (PD-L1) combined positive scores (CPS). The diagnostic value of CPS as a biomarker for NACI efficacy was enhanced when combined with total cholesterol level. The 3-year estimated DFS rates were 89.0% in the NACI cohort compared to 60.8% in the non-NACI cohort, while the 3-year estimated OS rates were 91.3 versus 64.0%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The NACI treatment showed safe and encouragingly efficacious for locally advanced resectable OSCC patients. The high response rates and favorable prognosis suggest this approach as a potential treatment option. Prospective randomized controlled trials are needed to further validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000001891","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:34:45Z","timestamp":1719509685000},"page":"781-790","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study"],"prefix":"10.1097","volume":"111","author":[{"given":"Bowen","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shule","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaobin","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunxing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxin","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haigang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University"},{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1]]},"reference":[{"key":"R1-20260304","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck cancer","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"key":"R2-20260304","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1097\/JS9.0000000000000489","article-title":"Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial)","volume":"109","author":"Huang","year":"2023","journal-title":"Int J Surg"},{"key":"R3-20260304","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cac2.12009","article-title":"Global and regional burdens of oral cancer from 1990 to 2017: Results from the global burden of disease study","volume":"40","author":"Ren","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"R4-20260304","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R5-20260304","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"key":"R6-20260304","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R7-20260304","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41368-021-00131-7","article-title":"Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma","volume":"13","author":"Elmusrati","year":"2021","journal-title":"Int J Oral Sci"},{"key":"R8-20260304","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(21)00076-0","article-title":"Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis","volume":"22","author":"Petit","year":"2021","journal-title":"Lancet Oncol"},{"key":"R9-20260304","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1172\/JCI161400","article-title":"Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-\u03b2 blockade in HPV-unrelated head and neck cancer","volume":"132","author":"Redman","year":"2022","journal-title":"J Clin Invest"},{"key":"R10-20260304","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J Clin Invest"},{"key":"R11-20260304","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"R12-20260304","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41368-020-0084-8","article-title":"Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma","volume":"12","author":"Mei","year":"2020","journal-title":"Int J Oral Sci"},{"key":"R13-20260304","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"R14-20260304","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"R15-20260304","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol"},{"key":"R16-20260304","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"R17-20260304","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"R18-20260304","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a Phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"key":"R19-20260304","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R20-20260304","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R21-20260304","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discov"},{"key":"R22-20260304","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"R23-20260304","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"R24-20260304","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"R25-20260304","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R26-20260304","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"R27-20260304","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck"},{"key":"R28-20260304","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"R29-20260304","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: from molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol"},{"key":"R30-20260304","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","article-title":"Navigating metabolic pathways to enhance antitumour immunity and immunotherapy","volume":"16","author":"Li","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R31-20260304","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41556-018-0217-x","article-title":"Metabolism as a guiding force for immunity","volume":"21","author":"Jung","year":"2019","journal-title":"Nat Cell Biol"},{"key":"R32-20260304","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","article-title":"Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"key":"R33-20260304","doi-asserted-by":"crossref","first-page":"937406","DOI":"10.3389\/fimmu.2022.937406","article-title":"Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: a potential approach for tumor therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"R34-20260304","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3945\/ajcn.115.124321","article-title":"Lipid biomarkers and long-term risk of cancer in the Women\u2019s Health Study","volume":"103","author":"Chandler","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"R35-20260304","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CJI.0000000000000321","article-title":"The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors","volume":"43","author":"Perrone","year":"2020","journal-title":"J Immunother"},{"key":"R36-20260304","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.it.2021.11.007","article-title":"The cholesterol pathway: impact on immunity and cancer","volume":"43","author":"King","year":"2022","journal-title":"Trends Immunol"},{"key":"R37-20260304","doi-asserted-by":"crossref","first-page":"e052373","DOI":"10.1136\/bmjopen-2021-052373","article-title":"Relationship between serum lipid level and colorectal cancer: a systemic review and meta-analysis","volume":"12","author":"Yang","year":"2022","journal-title":"BMJ Open"},{"key":"R38-20260304","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40001-022-00784-y","article-title":"The association between serum lipid levels and histological type of breast cancer","volume":"27","author":"Wang","year":"2022","journal-title":"Eur J Med Res"},{"key":"R39-20260304","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00262-023-03398-3","article-title":"The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors","volume":"72","author":"Perrone","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"R40-20260304","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12916-022-02696-4","article-title":"Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial","volume":"20","author":"Zhu","year":"2022","journal-title":"BMC Med"},{"key":"R41-20260304","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1038\/s41467-022-33080-8","article-title":"A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma","volume":"13","author":"Ju","year":"2022","journal-title":"Nat Commun"},{"key":"R42-20260304","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.2012.43.8820","article-title":"Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma","volume":"31","author":"Zhong","year":"2013","journal-title":"J Clin Oncol"},{"key":"R43-20260304","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cac2.12136","article-title":"Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome","volume":"41","author":"Ju","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R44-20260304","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"R45-20260304","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"R46-20260304","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.2147\/CMAR.S304022","article-title":"Baseline serum cholesterol levels predict the response of patients with advanced non-small cell lung cancer to immune checkpoint inhibitor-based treatment","volume":"13","author":"Tong","year":"2021","journal-title":"Cancer Manag Res"},{"key":"R47-20260304","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.phrs.2014.06.013","article-title":"Novel prospects of statins as therapeutic agents in cancer","volume":"88","author":"Pisanti","year":"2014","journal-title":"Pharmacol Res"},{"key":"R48-20260304","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/cncr.33797","article-title":"Association of statin use with clinical outcomes in patients with triple-negative breast cancer","volume":"127","author":"Nowakowska","year":"2021","journal-title":"Cancer"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:05:58Z","timestamp":1772625958000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001891","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"2023-11-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}